knowledge -WSS

knowledge

author：comprehensive 2025-09-29 15:04:32 - browse：22

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why scientists need input from humanists on sensitive research

entertainment

WSS

Readout Newsletter: CAR

Readout Newsletter: CAR

RSV vaccines may be linked to small increased risk of developing GBS

Ebola: Gilead Sciences antiviral shows promise as new treatment

FDA advisers back CAR

In search for therapies for solid tumors, companies turn to claudin

leisure time

knowledge

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Medical device lobby: We're tired of waiting on Medicare coverage

New air purifier tech could be key to improving indoor air quality

UCLA team creates talking throat patch for voice disorders

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare outage fallout shows need for new oversight

Apple is now the first public company to be valued at $3 trillion

AstraZeneca loses challenge to Medicare drug price negotiation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

ALS groups 'won't be played again' by the FDA, drug sponsors

FogPharma raises $145 million in rare Series E round

President Biden's budget: Here's what you might have missed

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Wikipedia

hotspot

entertainment

focus